Effectiveness of vitamin K2 on osteoporosis in adults with cerebral palsy

Publication date: Available online 16 June 2017
Source:Brain and Development
Author(s): Yuichi Kodama, Yasuhiro Okamoto, Tomohiro Kubota, Yoshifumi Hiroyama, Hiroshi Fukami, Kensuke Matsushita, Yoshifumi Kawano
BackgroundOsteoporosis can lead to spontaneous fractures in adults with cerebral palsy (CP). Undercarboxylated osteocalcin (ucOC) is a useful marker for vitamin K insufficiency in osteoporosis. The primary objective of this study was to determine the effect of vitamin K2 on bone mineral density (BMD) in adults with CP and vitamin K insufficiency.MethodsSixteen adults, median age of 56years, with CP and osteoporosis in whom the serum ucOC concentration exceeded 4.5ng/mL were included. All patients received 45mg of vitamin K2 per day. BMD was measured and presented as a percentage of the young adult mean (%YAM). Serum levels of ucOC and BMD were measured at baseline and after 6 and 12months.ResultsSerum levels of ucOC decreased from 7.8ng/mL (range, 4.9–32) at baseline to 3.9ng/mL (range, 1.9–6.8) after 6months (P=0.001). BMD increased from 59%YAM (range, 45–67) at baseline to 68%YAM (range, 50–79) after 12months (P=0.003).ConclusionsVitamin K2 had a positive effect on BMD in osteoporotic adults with CP and high serum concentrations of ucOC, and might be useful as a first line treatment for osteoporotic adults with CP and vitamin K insufficiency.



http://ift.tt/2rzXB5K